Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. 소양증을 동반한 아토피성 피부염에 대한 Nemolizumab 및 국소제의 시험

Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.